Prediction of clinicopathological features, multi-omics events and prognosis based on digital pathology and deep learning in HR+/HER2− breast cancer
Concordance
Progesterone receptor
DOI:
10.21037/jtd-23-445
Publication Date:
2023-05-30T03:12:51Z
AUTHORS (6)
ABSTRACT
Background: Breast cancer has the highest incidence and mortality rates among women worldwide. Hormone receptor (HR)+/human epidermal growth factor 2 (HER2)− breast is most common molecular subtype, accounting for 50–79% of cancers. Deep learning been widely used in image analysis, especially predicting targets related to precise treatment patient prognosis. However, studies focusing on therapeutic target prognosis HR+/HER2− are lacking. Methods: This study retrospectively collected hematoxylin eosin (H&E)-stained slides patients between January 2013 December 2014 at Fudan University Shanghai Cancer Center (FUSCC) scanned generate whole-slide images (WSIs). Then, we built a deep-learning-based workflow train validate model predict clinicopathological features, multi-omics features prognosis; area under curve (AUC) receiver operating characteristic (ROC) concordance index (C-index) test set were assess effectiveness. Results: A total 421 included our study. Regarding grade III could be predicted with an AUC 0.90 [95% confidence interval (CI): 0.84–0.97]. somatic mutations, TP53 GATA3 mutation AUCs 0.68 (95% CI: 0.56–0.81) 0.47–0.89), respectively. gene enrichment analysis (GSEA) pathways, G2-M checkpoint pathway was 0.79 0.69–0.90). markers immunotherapy response, intratumoral tumor-infiltrating lymphocytes (iTILs), stromal (sTILs), CD8A, PDCD1 0.78 0.55–1.00), 0.76 0.65–0.87), 0.71 0.60–0.82), 0.74 0.63–0.85), In addition, found that integration clinical prognostic variables deep can improve stratification Conclusions: Using workflow, developed models using pathological WSIs. work may contribute efficient promote personalized management cancer.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (6)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....